Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
RIBOCICLIB, Kisqali 200 mg film-coated tablets
The George Institute
Hormone receptor–positive (HRpos)/human epidermal growth factor receptor 2–negative (HER2neg) early breast cancer at risk of recurrence
1 trial -
ROSUVASTATIN AND EZETIMIBE , BEMPEDOIC ACID , ROSUVASTATIN AND EZETIMIBE , ATORVASTATIN AND AMLODIPINE
The George Institute
CHRONIC INFLAMMATORY RHEUMATIC DISEASE: rheumatoid arthritis or psoriatic arthritis or axial spondyloarthritis or systemic lupus erythematosus
1 trial -
Rabipur Pulver und Lösungsmittel zur Herstellung einer Injektionslösung in einer Fertigspritze Tollwut-Impfstoff (inaktiviert), RABIPUR, poudre et solvant pour solution injectable en seringue préremplie. Vaccin rabique (inactivé)., Rabipur poeder en oplosmiddel voor oplossing voor injectie in een voorgevulde spuit.Rabiësvaccin (geïnactiveerd).
The George Institute
rabies pre-exposure prophylaxis
1 trial -
Rapamune 1 mg coated tablets, MYCOPHENOLATE MOFETIL
The George Institute
End-stage kidney disease in Type 1 diabetes, SIROLIMUS VERSUS MYCOPHENOLATE MOFETIL IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION TO EVALUATE THE RISK OF HERNIA
1 trial -
Recigarum 1,5 mg comprimidos recubiertos con película EFG
The George Institute
Active smokers
1 trial -
Rifaldin 300 mg cápsulas, Rimactán 300 mg cápsulas duras, Cemidón 300 B6, RIFAPENTINE
The George Institute
Latent tuberculosis infection in patients with end-stage kidney disease.
1 trial -
Ropivacaine B. Braun 10 mg/ml injektionsvätska, lösning
The George Institute
lumbar arthrodesis
1 trial -
SILDENAFIL , LEVOTHYROXINE SODIUM
The George Institute
erectile function, hypothyroidism subclinic
1 trial -
SINECATECHINS
The George Institute
Anal high-grade squamous intraepithelial lesions (HSIL).
1 trial -
SUMATRIPTAN , GLYCERYL TRINITRATE , RIMEGEPANT
The George Institute
Migraine
1 trial -
Sitagliptin 50mg Film-coated Tablets, Trajenta 5 mg film-coated tablets, Pioglitazone Mylan 15 mg compresse, Ozempic 0.5 mg solution for injection in pre-filled pen, Jardiance 10 mg film-coated tablets, GLUCOPHAGE 1000 mg potahované tablety, Invokana 100 mg film-coated tablets, Trulicity 1.5 mg solution for injection in pre-filled pen, Galvus 50 mg tablets, Forxiga 10 mg film-coated tablets
The George Institute
Type 2 Diabetes Mellitus
1 trial -
Sulfato de Magnesio Altan 150 mg/ml solución inyectable y para perfusión EFG, LIDOCAINE HYDROCHLORIDE, Dexdor 100 micrograms/ml concentrate for solution for infusion, KETOLAR 50 mg/ml solución inyectable.
The George Institute
Obesity
1 trial -
TACROLIMUS, SIROLIMUS, MYCOPHENOLATE MOFETIL, AZATHIOPRINE, PREDNISOLONE, EVEROLIMUS, MYCOPHENOLIC ACID, BELATACEPT, CICLOSPORIN
The George Institute
BK Polyomavirus DNAemia after kidney transplantation
1 trial -
TESTOGEL 50 mg gel transdérmico en sobres, Decapeptyl diario 0,1 mg polvo y disolvente para solución inyectable, Bemfola 300 IU/0.50 mL solution for injection in pre-filled pen, Astarté 0,25 mg/0,5 ml solución inyectable en jeringa precargada EFG
The George Institute
low ovarian reserve according to Bologna criteria and carriers of androgen receptor polymorphism
1 trial -
TRANEXAMIC ACID
The George Institute
Hip fracture
1 trial -
Trangorex 200 mg comprimidos
The George Institute
Atrial fibrillation
1 trial -
Ultomiris 300 mg/30 mL concentrate for solution for infusion
The George Institute
IgA nephropathy
1 trial -
Urapidil Accord 5 mg/ml solución inyectable y para perfusión EFG, Trandate 5mg/ml Solution for Injection, Fenilefrina Altan 0,1 mg/ml solución inyectable y para perfusión.
The George Institute
Acute Ischemic Stroke
1 trial -
Vabysmo 120 mg/mL solution for injection in pre-filled syringe
The George Institute
SUBRETINAL HYPERREFLECTIVE MATERIAL
1 trial -
Vyvgart 20 mg/mL concentrate for solution for infusion
The George Institute
Patients affected by generalized myasthenia gravis
1 trial -
Wegovy 2.4 mg solution for injection in pre-filled pen
The George Institute
obstructive sleep apnea
1 trial -
Xtandi - 40 mg soft capsules
The George Institute
PROSTATE CANCER
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources